#United States #Atlanta #Altesa BioSciences #Vapendavir #COPD Treatment

Altesa BioSciences Showcases Breakthrough Findings at ERS 2025

Altesa BioSciences Inc., a clinical-stage pharmaceutical company, has achieved a significant milestone by being selected for a late-breaker presentation at the European Respiratory Society (ERS) International Congress 2025 scheduled in Amsterdam. The company is making headlines with their innovative treatment aimed at alleviating Chronic Obstructive Pulmonary Disease (COPD) and asthma exacerbations, recognizing the necessity of viable therapeutic options for these chronic conditions.

Vapendavir: A New Hope

the spotlight during the congress will shine on Vapendavir, an oral capsid inhibitor designed to battle rhinovirus, a major culprit behind COPD exacerbations. The abstract titled "Vapendavir for the Treatment of COPD Patients Challenged with Rhinovirus: A Phase 2a Placebo-Controlled Study" encapsulates findings from a recent randomized trial focused on this promising treatment, targeting GOLD stage II COPD patients exposed to rhinovirus A16. This comprehensive study signifies a leap towards identifying effective strategies against virus-induced exacerbations in COPD—a realm currently lacking targeted therapies.

Study Results and Implications

the findings unveiled during this research presented numerous improvements across various patient-reported outcomes (PROs). Participants exhibited significant reductions in upper and lower airway symptoms, alongside physiological biomarker enhancements. These notable outcomes were recognized through endpoints authenticated by both the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA), showcasing the scientific and clinical rigor behind the study.

Dr. Katharine Knobil, Chief Medical Officer of Altesa, shared her enthusiasm for the breakthrough, stating that "these results represent a potential breakthrough in managing viral-induced exacerbations in COPD, as no targeted therapies currently exist to address this unmet need." Her insights signify the potential shift Vapendavir could create in the treatment and management landscape for millions living with chronic lung diseases.

Presentation in Amsterdam

the study presentation will take place during the late-breaker session on September 30, 2025, led by Professor Sebastian Johnston, a renowned expert in respiratory medicine from the National Heart & Lung Institute at Imperial College London. This presentation is set to garner attention, not only for its clinical implications but also for the broader discussions on emerging treatment paradigms in COPD management.

Beyond the late-breaker session, the research data will also be extensively discussed in an Industry Symposium scheduled for September 28, 2025, at ERS Congress 2025. Esteemed pulmonary experts, including Professor Wisia Wedzicha, will elucidate the broader applicability of Vapendavir in clinical settings, addressing the pressing need for effective treatments against viral exacerbations in patients with chronic lung conditions.

Future Directions for Altesa

the momentum generated from the ERS Congress 2025 marks just one step in Altesa's ambitious roadmap. The company is gearing up to initiate a multicenter, multinational randomized controlled Phase 2b trial targeting COPD patients experiencing natural rhinovirus infections. The groundwork for this vast study will be laid by early 2026, with topline results anticipated by late 2027. This strategic phase heralds the next chapter in performance assessment for Vapendavir, further validating its capabilities in real-world applications against chronic respiratory ailments.

About Vapendavir

a compelling aspect of Vapendavir is its unique therapeutic profile. Designed to cut through the complexities of viral respiratory infections, Vapendavir has emerged with the promise of preventing up to 50% of COPD exacerbations. Its potential benefits extend beyond just symptom management, aiming to enhance patients' quality of life, longevity, and significantly reduce financial burdens by minimizing the need for costly immune-modifying injections.

About Altesa BioSciences Inc.

altesa BioSciences is spearheaded by a dedicated team of leaders in respiratory medicine and infectious disease, focused on revolutionizing therapeutic approaches for individuals grappling with chronic respiratory diseases. By targeting viral infections—the primary instigators behind exacerbations—Altesa is setting a benchmark in how respiratory conditions are treated and managed, advocating for improved access to modern diagnostics and therapies for underserved communities.

In summation, Altesa BioSciences is not only presenting innovative research at ERS 2025 but is also illustrating its commitment to transforming the care landscape for COPD through Vapendavir. The eagerly awaited discussions in Amsterdam will undoubtedly shed light on the transformative potential of this groundbreaking therapy, placing a spotlight on the urgent need for effective solutions in managing chronic lung conditions.